A study on efficacy of Ezetimibe in patients with Dyslipidemia associated with Digestive disease-Its effect on biliary bigly metabolism-

A study on efficacy of Ezetimibe in patients with Dyslipidemia associated with Digestive disease-Its effect on biliary bigly metabolism- - A study on efficacy of Ezetimibe in patients with Dyslipidemia associated with Digestive disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004183

Enrollment

Registered

2010-09-10

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypercholesterolemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypercholesterolemia(LDL-C of 14mg/dL or more)

Exclusion criteria

Exclusion criteria: 1)Patients who are treated with insulin 2)HbA1>=8% 3)History ofhypersensitivity to Ezetimibe 4)Serious hepatic disfunctions 5)Patient whom biliary tract comletely blockaded 6)Serious kidney disfunctions 7)AMI,angina and stroke within 3 months before intervention 8)Secondary hypercholesterolemia or medical hypercholesterolemia 9)Pregnant or lactating women and women who may be pregnant 10)Familial hypercholesterolemia 11)Bronchial Asthma or an allergic disease 12)Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
Before and after 6 months of Ezetimibe to clinical effectiveness and bile composition	—

Countries

Japan

Contacts

Public ContactTazuma Susumu

Hiroshima University hospital Department of General Medicine

stazuma@hiroshima-u.ac.jp082-257-5461

Outcome results